Pfizer Obtains Clearance from Federal Cartel Office of Germany for Acquisition of All Outstanding Shares of Encysive Pharmaceuti

  
    
  
  
    
      Pfizer Inc (NYSE:PFE) announced today that it has obtained clearance 
      from the Federal Cartel Office of Germany (FCO) in connection with the 
      tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., 
      to purchase all of the outstanding shares of common stock of Encysive 
      Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per 
      share, net to the seller in cash, without interest thereon and less any 
      required withholding taxes.
    
    
      The “Regulatory Condition” 
      necessary for the consummation of the tender offer as defined and 
      described in the offer to purchase has now been satisfied. The tender 
      offer is scheduled to expire at 12:00 midnight, New York City time, on 
      Monday, March 31, 2008, unless extended in accordance with the 
      procedures described in the offer to purchase. The tender offer remains 
      conditioned upon the other closing conditions described in the offer to 
      purchase.
    
    
      Additional Information
    
    
      This press release is for informational purposes only and is neither an 
      offer to purchase nor a solicitation of an offer to sell securities. The 
      tender offer is being made pursuant to a tender offer statement and 
      related materials. The tender offer statement (including the offer to 
      purchase, letter of transmittal and related tender offer documents) 
      filed by Pfizer with the Securities and Exchange Commission (the “SEC”) 
      and the solicitation/recommendation statement filed by Encysive with the 
      SEC contain important information which should be read carefully before 
      any decision is made with respect to the tender offer.
    
    
      The offer to purchase and related materials as well as the 
      solicitation/recommendation statement may be obtained by Encysive 
      stockholders at no charge by directing a request by mail to Georgeson 
      Inc., 199 Water Street, 26th Floor, New York, NY 10038, or by calling 
      toll-free at [phone], and may also be obtained at no charge at 
      the website maintained by the SEC at http://www.sec.gov.
    
    
      DISCLOSURE NOTICE: The information contained in this press 
      release is as of March 27, 2008. Except as required by law, 
      Pfizer assumes no obligation to update any forward-looking statements 
      contained in this release as a result of new information or future 
      events or developments. Some statements in this release may 
      constitute forward-looking statements. Pfizer cautions that these 
      forward-looking statements are subject to risks and uncertainties that 
      may cause actual results to differ materially from those indicated in 
      the forward-looking statements, including the risk that the tender offer 
      may not be completed or the subsequent merger may not be consummated for 
      various reasons, including the failure to satisfy the conditions 
      precedent to the completion of the acquisition. A further list 
      and description of risks and uncertainties can be found in Pfizer’s 
      Annual Report on Form 10-K for the fiscal year ended December 31, 2007 
      and in its subsequently filed reports on Forms 10-Q and 8-K.